BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will host an investor call on Monday, March 6 at 7:30 am ET to discuss Phase 2 Cohort 5 data from its PROPEL2 clinical trial of the investigational therapy infigratinib in children with achondroplasia. Infigratinib is an oral small molecule designed to inhibit fibroblast growth factor receptor 3 (FGFR3) and target achondroplasia at its source.
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the United States (US) and European Union (EU), including up to 10,000 children and adolescents with open growth plates. Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. The condition is uniformly caused by an activating mutation in FGFR3.
To access the live webcast, please visit the “Events” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.